Phaseline

Companies › I-Mab Biopharma US

I-Mab Biopharma US: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TJ033721 (givastomig)
anti-CLDN18.2 antibody-drug conjugate
CLDN18Phase 2Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04900818TJ033721 (givastomig)Phase 1Solid TumorOncologyDec 2026
NCT07432295TJ033721 (givastomig)Phase 2Solid TumorOncologyMar 2030

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Companies built like this

NingBo Junyan Hongshi Biosciences Biokin (Shanghai) Biopharmaceutical CrystalGenomics Partner Therapeutics STCube

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.